

## ANTIPSORIATICS, ORAL PRIORITY AUTHORIZATION FORM

- Please submit **all** requested documentation with this request. Incomplete documentation may delay the processing of this request.
- Prior authorization guidelines for **Antipsoriatics, Oral** and **Quantity Limits/Daily Dose Limits** are available on the DHS Pharmacy Services website at: <http://www.dhs.pa.gov/provider/pharmacyservices/drugsrequiringclinicalpriorauthorization/index.htm>.

PRIOR AUTHORIZATION INFORMATION		PRESCRIBER INFORMATION	
<input type="checkbox"/> New request	<input type="checkbox"/> Renewal request	# of pages: _____	
Name of office contact:		Prescriber name:	
Contact's phone number:		Specialty:	
LTC facility contact/phone:		State license #:	MA Provider ID#:
<b>BENEFICIARY INFORMATION</b>		Street address:	
Beneficiary name:		Suite #:	City/state/zip:
Beneficiary ID#:	DOB:	Phone:	Fax:

### CLINICAL INFORMATION

<b>Non-preferred medication requested:</b>	<input type="checkbox"/> methoxsalen rapid capsule <input type="checkbox"/> OxSORALEN-Ultra soft gelatin capsule <input type="checkbox"/> Soriatane capsule		
Strength:	Dose/directions:	Quantity:	Refills:
Diagnosis ( <i>submit documentation</i> ):		DX code ( <i>required</i> ):	
1. Does the beneficiary have a history of trial and failure, contraindication, or intolerance of the preferred Antipsoriatic, Oral agent, <b>acitretin capsule</b> ?		<input type="checkbox"/> Yes – <i>Submit all supporting documentation of preferred agents tried and treatment outcomes, including contraindications or intolerances.</i>  <input type="checkbox"/> No	

**PLEASE FAX COMPLETED FORM WITH REQUIRED CLINICAL DOCUMENTATION TO DHS – PHARMACY DIVISION**

<b>Prescriber Signature:</b>	<b>Date:</b>
------------------------------	--------------

**Confidentiality Notice:** The documents accompanying this telecopy may contain confidential information belonging to the sender. The information is intended only for the use of the individual named above. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or taking of any telecopy is strictly prohibited.